|
|
Article: NexBio(R) Presents Data Showing Anti-Asthma Activity of DAS181 (Fludase(R)*) at ACAAI 2009.
- Article from:
- PR Newswire
- Article date:
- November 9, 2009
CopyrightCOPYRIGHT 2009 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
SAN DIEGO, Nov. 9 /PRNewswire/ -- NexBio, Inc. announced the presentation of new data at the 2009 annual American College of Allergy, Asthma, and Immunology in Miami, Florida. The presentation was entitled "DAS181 (FludaseA'), a Sialidase, Decreases Airway Resistance and Has Potent Anti-inflammatory Effects in Animal Models of Asthma".
DAS181 (FludaseA') is an investigational broad spectrum host-targeting drug candidate being studied in human clinical development for treatment and prevention of Influenza-Like Illness caused by any strains of influenza and parainfluenza. NexBio has recently announced the publication of two articles describing activity in ...